Application 216109
- Type
- NDA
- Sponsor
- HIKMA PHARMACEUTICALS USA, INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ANCEF | CEFAZOLIN | INJECTABLE;INJECTION | EQ 2GM/VIAL | No | No |
| 002 | ANCEF | CEFAZOLIN | INJECTABLE;INJECTION | EQ 3GM/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N216109-001 | CEFAZOLIN SODIUM | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | |
| N216109-002 | CEFAZOLIN SODIUM | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-20 04:57 UTC | 2023-12 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | ea1830bbd6c7… | |
| 2023-12-20 04:57 UTC | 2023-12 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | a72a2bbeb626… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 9b2671bbb829… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | a67488948f0b… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 3f0d92c62455… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 053a50430f4f… | |
| 2023-05-13 08:27 UTC | 2023-05 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 3bdfa0b2c4d7… | |
| 2023-01-26 05:58 UTC | 2023-01 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 3a93d1ddd44b… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | 3a93d1ddd44b… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N216109-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N216109-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2022-10-07 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefazolin | CEFAZOLIN | Civica, Inc. | 1367568c-7d27-479f-a4c5-58e99942f686 | 2025-11-01 | Warnings, Adverse reactions | 216109 NDA216109 |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 6c7761d3-c154-4802-9876-627cd42913f0 | 2024-12-31 | Warnings, Adverse reactions | 216109 NDA216109 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.